Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer:XPD-Lys751Glnpolymorphism strikes back

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

(2012) Marcello Tiseo et al.   LUNG CANCER

A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)

(2011) Michele Reni et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DNA Repair Capacity in Peripheral Lymphocytes Predicts Survival of Patients With Non–Small-Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy

(2011) Li-E Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy

(2011) Elisa Giovannetti et al.   PHARMACOGENOMICS

An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

(2010) Michele Reni et al.   ANTI-CANCER DRUGS

Treatment trends in metastatic pancreatic cancer patients: Is it time to change?

(2010) Michele Reni et al.   DIGESTIVE AND LIVER DISEASE

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

(2010) Shu-zhen Wei et al.   MEDICAL ONCOLOGY